Skip to main content
Year archive

MAYNE PHARMA GROUP LIMITED — 2022 filings

All 57 regulatory filings released by MAYNE PHARMA GROUP LIMITED (MYX) in 2022, sourced directly from the official regulator.

57 Filings
2022 Period
2022 filings (57)
Filing Released Lang
Section 708A cleansing notice 12 pages 305.1KB
Capital/Financing Update
2022-12-29 English
Notification of cessation of securities - MYX 4 pages 24.3KB
Regulatory Filings
2022-12-20 English
MYX signs license agreement for women's health products 4 pages 183.5KB
Capital/Financing Update
2022-12-04 English
Proposed issue of securities - MYX 6 pages 31.7KB
Capital/Financing Update
2022-12-04 English
AGM presentation and business and trading update 33 pages 991.3KB
AGM Information
2022-11-29 English
Chairman's Address to Shareholders 5 pages 269.7KB
AGM Information
2022-11-29 English
Results of Meeting 2 pages 294.8KB
Declaration of Voting Results & Voting Rights Announcements
2022-11-29 English
Mayne Pharma capital management update 2 pages 156.2KB
Capital/Financing Update
2022-10-27 English
2022 AGM Notice of meeting and shareholder pack 22 pages 1.6MB
AGM Information
2022-10-27 English
Consolidation/Split - MYX 5 pages 28.4KB
Share Issue/Capital Change
2022-10-27 English
Dividend/Distribution - MYX 8 pages 187.4KB
Notice of Dividend Amount
2022-10-27 English
Return of Capital - MYX 9 pages 135.4KB
Capital/Financing Update
2022-10-27 English
Notification of cessation of securities - MYX 4 pages 24.3KB
Regulatory Filings
2022-10-25 English
2022 Corporate Governance Statement and Appendix 4G 27 pages 780.2KB
Governance Information
2022-10-12 English
Annual Report to shareholders 84 pages 3.9MB
Annual Report
2022-10-12 English
Final Director's Interest Notice x2 4 pages 666.2KB
Director's Dealing
2022-10-03 English
Initial Director's Interest Notice 2 pages 134.4KB
Director's Dealing
2022-10-03 English
Mayne Pharma completes sale of Metrics Contract Services 1
Capital/Financing Update
2022-10-03 English
Mayne Pharma appoints new CEO 3 pages 159.1KB
Board/Management Information
2022-09-27 English
Notification regarding unquoted securities - MYX 7 pages 29.7KB
Share Issue/Capital Change
2022-09-12 English
Initial Director's Interest Notice 2 pages 219.1KB
Director's Dealing
2022-08-31 English
Non-Executive Director appointment and retirement 2 pages 147.4KB
Board/Management Information
2022-08-30 English
Notification of cessation of securities - MYX 4 pages 24.3KB
Regulatory Filings
2022-08-30 English
Appendix 4E and Statutory Accounts 76 pages 1.8MB
Annual Report
2022-08-25 English
2022 Full Year Media Release 6 pages 388.9KB
Annual Report
2022-08-25 English
2022 Full Year Investor Presentation 34 pages 2.8MB
Investor Presentation
2022-08-25 English
Mayne Pharma CEO announces plan to retire 2 pages 147.8KB
Board/Management Information
2022-08-18 English
Mayne Pharma announces sale of Metrics Contract Services 3 pages 187.8KB
Capital/Financing Update
2022-08-09 English
Ceasing to be a substantial holder 6 pages 204.8KB
Regulatory Filings
2022-08-09 English
FDA approval of HALOETTE, a generic version of NUVARING 2 pages 212.0KB
Regulatory Filings
2022-08-07 English
Update - Notification of buy-back - MYX 6 pages 27.1KB
Transaction in Own Shares
2022-08-01 English
NEXTSTELLIS nominated for 2022 Prix Galien USA Award 2 pages 179.7KB
Regulatory Filings
2022-08-01 English
Notification of cessation of securities - MYX 4 pages 24.4KB
Transaction in Own Shares
2022-08-01 English
Change of Director's Interest Notice 2 pages 252.2KB
Director's Dealing
2022-08-01 English
MYX and GoodRx announce NEXTSTELLIS DTC campaign 2 pages 246.1KB
Regulatory Filings
2022-07-28 English
NEXTSTELLIS oral contraceptive now available in Australia 2 pages 204.0KB
Regulatory Filings
2022-07-25 English
Mayne Pharma appoints new CFO 2 pages 146.6KB
Board/Management Information
2022-07-21 English
Notification of buy-back - MYX 5 pages 24.9KB
Transaction in Own Shares
2022-06-30 English
Notification of cessation of securities - MYX 4 pages 24.3KB
Regulatory Filings
2022-06-23 English
Change in substantial holding 6 pages 201.7KB
Regulatory Filings
2022-06-23 English
Wilsons investor conference presentation 16 pages 964.3KB
Investor Presentation
2022-05-25 English
Notice under ASX Listing Rule 3.10A 1 page 174.6KB
Major Shareholding Notification
2022-05-09 English
Mayne Pharma recipient of $4.8m Federal Government Grant 1
Capital/Financing Update
2022-05-08 English
Initial Director's Interest Notice 2 pages 218.9KB
Director's Dealing
2022-03-22 English
Non Executive Director Appointment 2 pages 147.0KB
Board/Management Information
2022-03-21 English
Final Director's Interest Notice 2 pages 226.4KB
Director's Dealing
2022-02-28 English
Half Yearly Report and Accounts 39 pages 4.8MB
Interim / Quarterly Report
2022-02-24 English
2022 Half Year Media Release 7 pages 325.0KB
Interim / Quarterly Report
2022-02-24 English
2022 Half Year Investor Presentation 35 pages 1.8MB
Investor Presentation
2022-02-24 English
Ceasing to be a substantial holder 4 pages 465.0KB
Major Shareholding Notification
2022-02-16 English
Mayne Pharma expands US dermatology portfolio 1 pag
Capital/Financing Update
2022-02-09 English
Notification of cessation of securities - MYX 4 pages 24.3KB
Regulatory Filings
2022-02-09 English
Becoming a substantial holder 7 pages 307.6KB
Major Shareholding Notification
2022-02-01 English
Initial Director's Interest Notice 2 pages 223.1KB
Director's Dealing
2022-01-31 English
Ceasing to be a substantial holder 5 pages 483.6KB
Major Shareholding Notification
2022-01-31 English
Non-Executive Director appointment and retirement 2 pages 156.2KB
Board/Management Information
2022-01-16 English
Mayne Pharma adds a generic PROTOPIC to US portfolio 2 pages 270.4KB
Regulatory Filings
2022-01-11 English